开云app官网登录入口网页版-官方正版

#一线维持治疗#

13篇内容 | 1142人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2190356, encodeId=7b4821903562e, content=<a href='/topic/show?id=0a9e922085f' target=_blank style='color:#2F92EE;'>#贝伐珠单抗#</a> <a href='/topic/show?id=779319429d6' target=_blank style='color:#2F92EE;'>#一线维持治疗#</a> <a href='/topic/show?id=41f54454653' target=_blank style='color:#2F92EE;'>#奥拉帕利#</a>, objectTitle=Ann. Oncol | 奥拉帕利联合贝伐珠单抗一线维持治疗卵巢癌：PAOLA-1/ENGOT-ov25试验的最终总生存期结果, objectType=article, longId=815325, objectId=ec7881532580, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240229/1709221569982_6145188.jpg, objectUrl=/article/show_article.do?id=ec7881532580, replyNumber=0, likeNumber=70, createdTime=2024-03-01, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ec7881532580, moduleTitle=Ann. Oncol | 奥拉帕利联合贝伐珠单抗一线维持治疗卵巢癌：PAOLA-1/ENGOT-ov25试验的最终总生存期结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ec7881532580)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1734769, encodeId=0a0b1e34769ab, content=<a href='/topic/show?id=779319429d6' target=_blank style='color:#2F92EE;'>#一线维持治疗#</a>, objectTitle=PRIME数据：PARP抑制剂一线维持治疗卵巢癌患者全人群获益, objectType=article, longId=724862, objectId=9d1fe248622b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d1fe248622b, replyNumber=0, likeNumber=84, createdTime=2023-03-20, rootId=0, userName=venlin, userId=a96233820512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d1fe248622b, moduleTitle=PRIME数据：PARP抑制剂一线维持治疗卵巢癌患者全人群获益, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9d1fe248622b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734768, encodeId=1f611e3476815, content=<a href='/topic/show?id=779319429d6' target=_blank style='color:#2F92EE;'>#一线维持治疗#</a>, objectTitle=New England Journal of Medicine：尼拉帕利一线维持治疗晚期卵巢癌, objectType=article, longId=220793, objectId=d997220e93d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d997220e93d1, replyNumber=0, likeNumber=67, createdTime=2022-08-16, rootId=0, userName=venlin, userId=a96233820512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d997220e93d1, moduleTitle=New England Journal of Medicine：尼拉帕利一线维持治疗晚期卵巢癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d997220e93d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734767, encodeId=398a1e3476795, content=<a href='/topic/show?id=779319429d6' target=_blank style='color:#2F92EE;'>#一线维持治疗#</a>, objectTitle=J Thorac Oncol：尼拉帕利一线维持治疗中国铂敏感的广泛期小细胞肺癌患者的3期临床试验结果, objectType=article, longId=210730, objectId=22a4210e30f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22a4210e30f6, replyNumber=0, likeNumber=106, createdTime=2021-06-30, rootId=0, userName=venlin, userId=a96233820512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22a4210e30f6, moduleTitle=J Thorac Oncol：尼拉帕利一线维持治疗中国铂敏感的广泛期小细胞肺癌患者的3期临床试验结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=22a4210e30f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734766, encodeId=ea001e3476651, content=<a href='/topic/show?id=779319429d6' target=_blank style='color:#2F92EE;'>#一线维持治疗#</a>, objectTitle=姚书忠教授：PARP抑制剂一线维持治疗生物标志物从BRCA+到HRD+，HRD Score检测助力卵巢癌获益人群筛查, objectType=article, longId=196133, objectId=03921961335e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03921961335e, replyNumber=0, likeNumber=78, createdTime=2020-12-10, rootId=0, userName=venlin, userId=a96233820512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03921961335e, moduleTitle=姚书忠教授：PARP抑制剂一线维持治疗生物标志物从BRCA+到HRD+，HRD Score检测助力卵巢癌获益人群筛查, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=03921961335e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734765, encodeId=74031e3476577, content=<a href='/topic/show?id=779319429d6' target=_blank style='color:#2F92EE;'>#一线维持治疗#</a>, objectTitle=FDA扩展PARP抑制剂Zejula的适应症，用作晚期卵巢癌的一线维持治疗, objectType=article, longId=193374, objectId=b40b1933e4d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b40b1933e4d3, replyNumber=0, likeNumber=84, createdTime=2020-09-06, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b40b1933e4d3, moduleTitle=FDA扩展PARP抑制剂Zejula的适应症，用作晚期卵巢癌的一线维持治疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b40b1933e4d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734761, encodeId=4ec21e347616b, content=<a href='/topic/show?id=779319429d6' target=_blank style='color:#2F92EE;'>#一线维持治疗#</a>, objectTitle=JCO：GOG-0218最终OS结果出炉：贝伐珠单抗一线维持治疗卵巢癌未能改善生存, objectType=article, longId=174675, objectId=e49b1e46756a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e49b1e46756a, replyNumber=0, likeNumber=79, createdTime=2019-08-11, rootId=0, userName=venlin, userId=a96233820512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e49b1e46756a, moduleTitle=JCO：GOG-0218最终OS结果出炉：贝伐珠单抗一线维持治疗卵巢癌未能改善生存, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e49b1e46756a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734764, encodeId=81801e34764aa, content=<a href='/topic/show?id=779319429d6' target=_blank style='color:#2F92EE;'>#一线维持治疗#</a>, objectTitle=FDA接受葛兰素史克的补充新药申请，将其PARP抑制剂Zejula用作对铂类化疗敏感、晚期卵巢癌患者的一线维持治疗, objectType=article, longId=188795, objectId=27b9188e9585, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27b9188e9585, replyNumber=0, likeNumber=89, createdTime=2020-07-06, rootId=0, userName=venlin, userId=a96233820512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27b9188e9585, moduleTitle=FDA接受葛兰素史克的补充新药申请，将其PARP抑制剂Zejula用作对铂类化疗敏感、晚期卵巢癌患者的一线维持治疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=27b9188e9585)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734763, encodeId=c6251e34763fc, content=<a href='/topic/show?id=779319429d6' target=_blank style='color:#2F92EE;'>#一线维持治疗#</a>, objectTitle=解读PRIMA研究：卵巢癌一线维持治疗突破限制，进入2.0全人群时代, objectType=article, longId=182271, objectId=22b11822e1cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22b11822e1cc, replyNumber=0, likeNumber=86, createdTime=2020-06-15, rootId=0, userName=venlin, userId=a96233820512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22b11822e1cc, moduleTitle=解读PRIMA研究：卵巢癌一线维持治疗突破限制，进入2.0全人群时代, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=22b11822e1cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734762, encodeId=04c61e3476256, content=<a href='/topic/show?id=779319429d6' target=_blank style='color:#2F92EE;'>#一线维持治疗#</a>, objectTitle=JAMA Oncol：VALENTINO研究：帕尼单抗一线维持治疗RAS野生型结直肠癌劣于帕尼单抗联合氟尿嘧啶, objectType=article, longId=175430, objectId=98161e54306c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98161e54306c, replyNumber=0, likeNumber=84, createdTime=2020-06-23, rootId=0, userName=venlin, userId=a96233820512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98161e54306c, moduleTitle=JAMA Oncol：VALENTINO研究：帕尼单抗一线维持治疗RAS野生型结直肠癌劣于帕尼单抗联合氟尿嘧啶, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=98161e54306c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734760, encodeId=c9691e34760e9, content=<a href='/topic/show?id=779319429d6' target=_blank style='color:#2F92EE;'>#一线维持治疗#</a>, objectTitle=【2018 ESMO ASIA】SOLO1研究：BRCA突变卵巢癌患者一线维持治疗结果喜人, objectType=article, longId=154850, objectId=6a581548506d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a581548506d, replyNumber=0, likeNumber=110, createdTime=2019-05-13, rootId=0, userName=venlin, userId=a96233820512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a581548506d, moduleTitle=【2018 ESMO ASIA】SOLO1研究：BRCA突变卵巢癌患者一线维持治疗结果喜人, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6a581548506d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734759, encodeId=92bd1e3475914, content=<a href='/topic/show?id=779319429d6' target=_blank style='color:#2F92EE;'>#一线维持治疗#</a>, objectTitle=【NEJM】SOLO 1研究：奥拉帕利进军晚期卵巢癌一线维持治疗, objectType=article, longId=152193, objectId=2532152193a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2532152193a4, replyNumber=0, likeNumber=80, createdTime=2019-02-12, rootId=0, userName=venlin, userId=a96233820512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2532152193a4, moduleTitle=【NEJM】SOLO 1研究：奥拉帕利进军晚期卵巢癌一线维持治疗, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2532152193a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734758, encodeId=c9531e3475870, content=<a href='/topic/show?id=779319429d6' target=_blank style='color:#2F92EE;'>#一线维持治疗#</a>, objectTitle=重复：J Clin Oncol：来那度胺用于DLBCL老年患者一线维持治疗结果喜人, objectType=article, longId=110434, objectId=236e110434c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=236e110434c4, replyNumber=0, likeNumber=83, createdTime=2017-12-28, rootId=0, userName=venlin, userId=a96233820512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=236e110434c4, moduleTitle=重复：J Clin Oncol：来那度胺用于DLBCL老年患者一线维持治疗结果喜人, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=236e110434c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1734757, encodeId=ac5a1e347571b, content=<a href='/topic/show?id=779319429d6' target=_blank style='color:#2F92EE;'>#一线维持治疗#</a>, objectTitle=ASCO更新Ⅳ期NSCLC一线维持治疗指南, objectType=article, longId=3171, objectId=605231e106, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=605231e106, replyNumber=0, likeNumber=99, createdTime=2011-12-19, rootId=0, userName=venlin, userId=a96233820512, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=605231e106, moduleTitle=ASCO更新Ⅳ期NSCLC一线维持治疗指南, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=605231e106)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

一线维持治疗

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#贝伐珠单抗# #一线维持治疗# #奥拉帕利#

Ann. Oncol | 奥拉帕利联合贝伐珠单抗一线维持治疗卵巢癌：PAOLA-1/ENGOT-ov25试验的最终总生存期结果

2024-03-01发表于上海

venlin (审核中...)

前往app查看评论内容

#一线维持治疗#

PRIME数据：PARP抑制剂一线维持治疗卵巢癌患者全人群获益

2023-03-20

venlin (审核中...)

前往app查看评论内容

#一线维持治疗#

New England Journal of Medicine：尼拉帕利一线维持治疗晚期卵巢癌

2022-08-16

venlin (审核中...)

前往app查看评论内容

#一线维持治疗#

J Thorac Oncol：尼拉帕利一线维持治疗中国铂敏感的广泛期小细胞肺癌患者的3期临床试验结果

2021-06-30

venlin (审核中...)

前往app查看评论内容

#一线维持治疗#

姚书忠教授：PARP抑制剂一线维持治疗生物标志物从BRCA+到HRD+，HRD Score检测助力卵巢癌获益人群筛查

2020-12-10

柳叶一刀 (审核中...)

前往app查看评论内容

#一线维持治疗#

FDA扩展PARP抑制剂Zejula的适应症，用作晚期卵巢癌的一线维持治疗

2020-09-06

venlin (审核中...)

前往app查看评论内容

#一线维持治疗#

JCO：GOG-0218最终OS结果出炉：贝伐珠单抗一线维持治疗卵巢癌未能改善生存

2019-08-11

venlin (审核中...)

前往app查看评论内容

#一线维持治疗#

FDA接受葛兰素史克的补充新药申请，将其PARP抑制剂Zejula用作对铂类化疗敏感、晚期卵巢癌患者的一线维持治疗

2020-07-06

venlin (审核中...)

前往app查看评论内容

#一线维持治疗#

解读PRIMA研究：卵巢癌一线维持治疗突破限制，进入2.0全人群时代

2020-06-15

venlin (审核中...)

前往app查看评论内容

#一线维持治疗#

JAMA Oncol：VALENTINO研究：帕尼单抗一线维持治疗RAS野生型结直肠癌劣于帕尼单抗联合氟尿嘧啶

2020-06-23

venlin (审核中...)

前往app查看评论内容

#一线维持治疗#

【2018 ESMO ASIA】SOLO1研究：BRCA突变卵巢癌患者一线维持治疗结果喜人

2019-05-13

venlin (审核中...)

前往app查看评论内容

#一线维持治疗#

【NEJM】SOLO 1研究：奥拉帕利进军晚期卵巢癌一线维持治疗

2019-02-12

venlin (审核中...)

前往app查看评论内容

#一线维持治疗#

重复：J Clin Oncol：来那度胺用于DLBCL老年患者一线维持治疗结果喜人

2017-12-28

venlin (审核中...)

前往app查看评论内容

#一线维持治疗#

ASCO更新Ⅳ期NSCLC一线维持治疗指南

2011-12-19

科室
- - 订阅+
  - 更多科室
工具
服务